MAP2K7 and melanoma: The three B-Raf/MEK combinations available (vemurafenib with cobimetinib, dabrafenib together with trametinib, and finally encorafenib with binimetinib) have greatly bettered the clinical effectiveness of BRAF V600-mutant advanced melanomas compared to B-Raf monotherapy, with improved progression-free survival and longer overall survival rates [62,63].